Stye Drug Market Report 2026

The stye drug market size has grown strongly in recent years. It will grow from $4.7 billion in 2025 to $5.02 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to rising incidence of bacterial eye infections, increasing use of topical antibiotic eye medications, growing awareness regarding ocular hygiene, expansion of retail pharmacy distribution networks, rising healthcare expenditure on ophthalmic treatments.

The stye drug market size is expected to see strong growth in the next few years. It will grow to $6.6 billion by 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing demand for rapid-acting ophthalmic therapies, growing adoption of teleophthalmology services, rising development of combination antibiotic and steroid drugs, expansion of online pharmacy penetration, increasing focus on personalized ocular treatment solutions. Major trends in the forecast period include increasing prevalence of bacterial eyelid infections, growing demand for over-the-counter ophthalmic medications, rising adoption of combination antibiotic and steroid therapies, expanding utilization of topical ophthalmic formulations, increasing awareness regarding eyelid hygiene and preventive eye care.

The rising prevalence of eye infections is expected to propel the growth of the stye drug market going forward. Eye infections refer to conditions caused by bacteria, viruses, or other pathogens that impact parts of the eye, including the eyelid, conjunctiva, or cornea, resulting in symptoms such as redness, swelling, and pain. The increase in eye infections is primarily driven by greater screen exposure and inadequate eye hygiene practices in developed economies. Stye drugs help treat eye infections by offering targeted therapies such as antibiotic ointments, anti-inflammatory medications, and lubricating solutions that assist in reducing the severity of infections and speeding up recovery. For instance, in June 2023, according to the Australian Institute of Health and Welfare, 74 children aged 5-9 were identified with active trachoma across 67 screened communities. Therefore, the increasing prevalence of eye infections is driving the growth of the stye drug market.

The growing exposure to screen time is expected to propel the growth of the stye drug market going forward. Screen time refers to the duration an individual spends using digital devices such as smartphones, computers, tablets, and televisions. The increasing prevalence of screen time is mainly driven by the rapid adoption of digital technology in daily personal, educational, and professional activities, which has resulted in individuals across all age groups spending longer hours in front of screens. Increased screen time leads to a reduced blinking rate, causing the tear film to deteriorate and leaving the ocular surface more susceptible, thereby contributing to eyelid gland inflammation and increasing the incidence of styes and chalazia. For instance, in November 2023, according to the Office of Communications (Ofcom), in May 2023, adults in the UK spent 76% of their daily online time (2 hours 47 minutes) on smartphones, reflecting an increase of 20 minutes compared to May 2022, when smartphones represented 69% of online time. Therefore, rising exposure to screen time is driving the growth of the stye drug market.

Leading companies operating in the stye drug market are focusing on developing advanced ophthalmic solutions, such as antibiotic eye drops, to improve infection control, reduce inflammation, and accelerate healing of eyelid conditions. Antibiotic eye drops are formulations developed to eliminate bacterial infections in the eye region, helping relieve symptoms such as swelling and redness associated with styes. For instance, in September 2025, Bausch + Lomb Corporation launched Soothe Antibiotic Drops in Canada. This product is designed to deliver effective antibacterial treatment for eye infections, supporting faster recovery and enhanced patient comfort, thereby strengthening the therapeutic options available in the stye drug market.

Major companies operating in the stye drug market are Johnson & Johnson Services Inc., Pfizer Inc., AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Alcon Inc., Sun Pharmaceutical Industries Ltd., Bausch & Lomb Corporation, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Santen Pharmaceutical Co. Ltd., Alkem Laboratories Limited, Chengdu Kanghong Pharmaceutical Group Co. Ltd., Mylan N. V., Sam Chun Dang Pharm Co. Ltd., Similasan AG, Laboratoires Théa SAS, Allergan plc.

North America was the largest region in the stye drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stye drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the stye drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A stye drug market consists of sales of ophthalmic ointment, warm compress therapy gel, and eyelid cleansing wipes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.